General

RCSI research suggests that anti-rejection medications for multiple kidney transplants increase the risk of skin cancer

RCSI Paper

A study led by researchers at RCSI (Royal College of Surgeons in Ireland) has analysed the pattern of skin cancer rates in kidney transplant patients, which suggests the increased risk is related to the anti-rejection medications.

The research is published in JAMA Dermatology and was a collaboration between the National Cancer Registry Ireland and the National Kidney Transplant Service in Beaumont Hospital.

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free